# A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

> **NCT02604914** · PHASE1 · COMPLETED · sponsor: **NeuroDerm Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** ND0612
- **DRUG:** LCIG

## Key facts

- **NCT ID:** NCT02604914
- **Lead sponsor:** NeuroDerm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-29
- **Primary completion:** 2016-06-30
- **Final completion:** 2016-06-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02604914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02604914, "A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02604914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*